Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place October 15-17, 2024.
加利福尼亞西萊克村，2024年10月9日（全球新聞社）—賽路斯公司（納斯達克：GNLX）一家晚期臨床階段的免疫腫瘤學公司，宣佈董事長、總裁兼首席執行官Thomas Zindrick先生將參加於2024年10月15日至17日舉辦的2024 Maxim Healthcare虛擬峯會。
Mr. Zindrick will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research, which is scheduled for 2:00 pm E.T. on October 15, 2024.
Zindrick先生將與生物技術研究主管、高級董事Jason McCarthy博士進行爐邊對話，討論臨床階段項目、最新公告以及即將到來的里程碑。該爐邊對話定於2024年10月15日美東時間下午2:00舉行。
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its' proprietary CHOICE platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit and follow us on Twitter @Genelux_Corp and on LinkedIn.
關於Genelux Corporation
Genelux是一家成熟的後期臨床階段生物製藥公司，專注於爲患有侵襲性和/或難以治療的固體腫瘤類型的患者開發下一代溶瘤免疫療法。該公司最先進的產品候選藥物Olvi-Vec (olvimulogene nanivacirepvec)是對天花病毒的專有修飾株系。Olvi-Vec目前正在進行OnPrime/GOG-3076臨床試驗，這是一項多中心、隨機、開放標籤的III期註冊試驗，評估Olvi-Vec與鉑金雙聯藥+ bevacizumab相比，與醫生選擇的化療藥物和bevacizumab聯合用於鉑金耐藥/難治性卵巢癌患者的療效和安全性。Genelux的發現和開發工作的核心是其專有的CHOICE平台，公司從這個平台上開發了大量的離體和工程化溶瘤天花病毒免疫治療產品候選物，包括Olvi-Vec。欲了解更多信息，請訪問 ，並關注我們的Twitter @Genelux_Corp和LinkedIn。
Investor and Media Contacts
投資者和媒體聯繫人
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Ankit Bhargava，MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
信息來源: 邁肯基因科技股份有限公司
Source: Genelux Corporation
信息來源: 邁肯基因科技股份有限公司
譯文內容由第三人軟體翻譯。
